Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CellSource Co., Ltd. (4880.T)
JPY345.00
-4.00 (-1.15%)
JP JPX Healthcare Biotechnology
Address
Shibuya Mitake Building 150-0002
Tokyo, JP
Tokyo, JP
CEO
Masayuki Yamakawa
Website
cellsource.co.jp
IPO
2019-10-29
ISIN JP3423580004
Description
CellSource Co., Ltd. operates within both the regenerative medicine and consumer product sectors. Among its offerings is Signalift, an anti-aging solution. The company, which was established in 2015, is headquartered in Tokyo, Japan.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
JPY345.00
-4.00 (-1.15%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
58.5K
Beta
-0.19
Float Shares
9.10M
Free Float %
45.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.66% | -8.28% | -17.17% | -20.90% | -31.26% | -25.25% | -58.24% | -90.01% | -93.36% | -61.67% | -61.67% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
345.00
DCF (Unlevered)
796.61
+130.9%
DCF (Levered)
1,113.59
+222.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2026-06 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
5.75
Safe zone
Piotroski F-Score
5 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-14.8% Q2'26: -5.7% (vs Q2'25)
-
EPS growth Biotechnology: +29.7%-95.5% Q2'26: -33.9% (vs Q2'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+6.6% Q2'26: +31.7% (vs Q2'25)
-
EBIT margin Biotechnology: +0.0%+4.5% ★ Q2'26: +7.2% (vs Q2'25)
-
ROIC Biotechnology: -16.1%+7.4% ★ Q2'26: +14.0% (vs Q2'25)
-
Share dilution Biotechnology: -3.4%0.0% ★ Q2'26: +0.3% (vs Q2'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.15× ★ Q2'26: 0.10× (vs Q2'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Oct 2020 actual |
Oct 2021 actual |
Oct 2022 actual |
Oct 2023 actual |
Oct 2024 actual |
Oct 2025 actual |
Oct 2026 2 Rev. Ana. 1 EPS Ana. |
Oct 2027 1 Rev. Ana. 1 EPS Ana. |
Oct 2028 1 Rev. Ana. 1 EPS Ana. |
Oct 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.86B
est: 1.87B (-0.8%)
|
2.92B
est: 2.95B (-0.9%)
|
4.27B
est: 4.09B (+4.5%)
|
4.51B
est: 4.70B (-4.0%)
|
4.36B
est: 4.38B (-0.6%)
|
3.71B
est: 3.77B (-1.6%)
|
3.70B
3.33B – 4.07B
-1.9% YoY
|
3.80B
3.60B – 4.00B
+2.7% YoY
|
4.10B
3.89B – 4.31B
+7.9% YoY
|
6.07B
5.75B – 6.39B
+48.1% YoY
|
| EBITDA |
478.91M
est: 522.77M (-8.4%)
|
1.05B
est: 824.69M (+27.0%)
|
1.63B
est: 1.14B (+42.8%)
|
1.29B
est: 1.31B (-1.9%)
|
282.38M
est: 1.04B (-72.9%)
|
371.03M
est: 897.79M (-58.7%)
|
881.12M
792.26M – 969.98M
-1.9% YoY
|
904.93M
857.48M – 952.38M
+2.7% YoY
|
976.37M
925.18M – 1.03B
+7.9% YoY
|
1.45B
1.37B – 1.52B
+48.1% YoY
|
| EBIT |
415.55M
est: 479.04M (-13.3%)
|
993.25M
est: 755.70M (+31.4%)
|
1.57B
est: 1.05B (+49.9%)
|
1.22B
est: 1.20B (+1.5%)
|
129.16M
est: 922.18M (-86.0%)
|
166.71M
est: 793.87M (-79.0%)
|
779.13M
700.55M – 857.70M
-1.9% YoY
|
800.19M
758.23M – 842.14M
+2.7% YoY
|
863.36M
818.09M – 908.63M
+7.9% YoY
|
1.28B
1.21B – 1.35B
+48.1% YoY
|
| Net Income |
274.08M
est: 272.01M (+0.8%)
|
651.40M
est: 634.24M (+2.7%)
|
1.02B
est: 938.49M (+8.5%)
|
923.14M
est: 998.13M (-7.5%)
|
237.94M
est: 424.40M (-43.9%)
|
10.66M
est: 111.40M (-90.4%)
|
100.00M
92.69M – 106.25M
-10.2% YoY
|
110.00M
101.96M – 116.87M
+10.0% YoY
|
190.00M
177.96M – 204.00M
+72.7% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
824.57M
est: 202.15M (+307.9%)
|
998.22M
est: 318.91M (+213.0%)
|
1.39B
est: 442.15M (+215.0%)
|
1.87B
est: 507.82M (+267.4%)
|
2.16B
est: 1.83B (+18.1%)
|
1.90B
est: 1.58B (+20.7%)
|
1.55B
1.39B – 1.70B
-1.9% YoY
|
1.59B
1.51B – 1.67B
+2.7% YoY
|
1.71B
1.62B – 1.80B
+7.9% YoY
|
2.54B
2.40B – 2.67B
+48.1% YoY
|
| EPS |
15.19
est: 13.67 (+11.1%)
|
35.17
est: 31.87 (+10.4%)
|
54.54
est: 47.15 (+15.7%)
|
48.88
est: 50.15 (-2.5%)
|
12.02
est: 21.30 (-43.6%)
|
0.54
est: 5.60 (-90.4%)
|
5.00
4.66 – 5.34
-10.7% YoY
|
5.50
5.13 – 5.87
+10.0% YoY
|
9.60
8.95 – 10.25
+74.5% YoY
|
—
— – —
-100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-10 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-09 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-08 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-05 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-04 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-03 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-02 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-06-01 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-21 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-13 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-12 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | B+ | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-01 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | B+ | 3/5 | 5/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
532.60M
OE per share TTM
26.82
Owner's Yield
8.98%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
13.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares Core TOPIX ETF 1475.T | 0.00% | 49.1K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
1.10M
Shares Outstanding
19.83M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hideto Kaneshima | Chief Technology Advisor | — | — |
| Masayuki Yamakawa | Chairman, CEO & President | — | male |
| Sei Sasaki | Executive Officer & Head of Medical Support Division | — | — |
| Tomohiro Iga | Executive Officer, Head of Corporate Division, CFO & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4880.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
